Cisplatin-resistant osteosarcoma cells possess cancer stem cell properties in a mouse model

Oncology Letters

Volumn 12, Issue 4, 2016, Pages 2599-2605

  Yang, Jian ^a   Guo, Weichun ^a   Wang, Lu ^a   Yu, Ling ^a   Mei, Hongjun ^b   Fang, Shuo ^a   Ji, Peng ^a   Liu, Yang ^a   Liu, Gaiwei ^a   Song, Qi ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b Wuhan No 4 Hospital   (China)

Author keywords

Cancer stem cells; Cisplatin; Osteosarcoma; Resistant

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; STEM CELL FACTOR RECEPTOR; TELOMERASE REVERSE TRANSCRIPTASE;

ANTIBIOTIC RESISTANCE; ARTICLE; CANCER RECURRENCE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL ISOLATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; MOUSE MODEL; NONHUMAN; OSTEOSARCOMA CELL; PHASE CONTRAST MICROSCOPY; POLYMERASE CHAIN REACTION; TUMOR CELL INOCULATION; TUMOR GROWTH; TUMOR VOLUME;

EID: 84983413668     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.4956     Document Type: Article

References (30)

1. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20: 776-790, 2002.
2. Cormier JN and Pollock RE: Soft tissue sarcomas. CA Cancer J Clin 54: 94-109, 2004.
3. Luetke A, Meyers PA, Lewis I and Juergens H: Osteosarcoma treatment-where do we stand? A state of the art review. Cancer Treat Rev 40: 523-532, 2014.
4. Janeway KA and Grier HE: Sequelae of osteosarcoma medical therapy: A review of rare acute toxicities and late effects. Lancet Oncol 11: 670-678, 2010.
5. Picci P, Ferrari S, Bacci G and Gherlinzoni F: Treatment recommendations for osteosarcoma and adult soft tissue sarcomas. Drugs 47: 82-92, 1994.
6. Meyers PA: Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther 9: 1035-1049, 2009.
7. Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D, et al: Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: Meeting summary. Clin Cancer Res 9: 5442-5453, 2003.
8. Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737, 1997.
9. Park CY, Tseng D and Weissman IL: Cancer stem cell-directed therapies: Recent data from the laboratory and clinic. Mol Ther 17: 219-230, 2009.
10. Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284, 2005.
11. Korkaya H and Wicha MS: Selective targeting of cancer stem cells: A new concept in cancer therapeutics. BioDrugs 21: 299-310, 2007.
12. Ma S, Lee TK, Zheng BJ, Chan KW and Guan XY: CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27: 1749-1758, 2008.
13. Adhikari AS, Agarwal N, Wood BM, Porretta C, Ruiz B, Pochampally RR and Iwakuma T: CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 70: 4602-4612, 2010.
14. Luu HH, Kang Q, Park JK, Si W, Luo Q, Jiang W, Yin H, Montag AG, Simon MA, Peabody TD, et al: An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis 22: 319-329, 2005.
15. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
16. Savage, S.A. and L. Mirabello, Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma, 2011. 2011: p. 548151.
17. Ek ET, Dass CR and Choong PF: Commonly used mouse models of osteosarcoma. Crit Rev Oncol Hematol 60: 1-8, 2006.
18. Chen X, Li Y, Xiong K, Aizicovici S, Xie Y, Zhu Q, et al. Cancer gene therapy by direct tumor injections of a nonviral T7 vector encoding a thymidine kinase gene. Human Gene Ther 1998; 9(5):729–36.
19. Crnalic S, Hakansson I, Boquist L, Lofvenberg R, Brostrom LA. A novel spontaneous metastasis model of human osteosarcoma developed using orthotopic transplantation of intact tumor tissue into tibia of nude mice. Clin Exp Metastasis 1997; 15(2):164–72.
20. Vergote J, Moretti JL, de Vries EG and Garnier-Suillerot A: Comparison of the kinetics of active efflux of 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes. Eur J Biochem 252: 140-146, 1998.
21. Suto R, Abe Y, Nakamura M, Ohnishi Y, Yoshimura M, Lee YH, Imanishi T, Yamazaki H, Kijima H, Tokunaga T, et al: Multidrug resistance mediated by overexpression of P-glycoprotein in human osteosarcoma in vivo. Int J Oncol 12: 287-291, 1998.
22. Chan HS, Grogan TM, Haddad G, DeBoer G and Ling V: P-glycoprotein expression: Critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 89: 1706-1715, 1997.
23. Burak Z, Moretti JL, Ersoy O, Sanli U, Kantar M, Tamgac F and Basdemir G: 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression. J Nucl Med 44: 1394-1401, 2003.
24. Dutour A, Leclers D, Monteil J, Paraf F, Charissoux JL, Rousseau R and Rigaud M: Non-invasive imaging correlates with histological and molecular characteristics of an osteosarcoma model: Application for early detection and follow-up of MDR phenotype. Anticancer Res 27: 4171-4178, 2007.
25. Beachy PA, Karhadkar SS and Berman DM: Tissue repair and stem cell renewal in carcinogenesis. Nature 432: 324-331, 2004.
26. Ravandi F, Burnett AK, Agura ED and Kantarjian HM: Progress in the treatment of acute myeloid leukemia. Cancer 110: 1900-1910, 2007.
27. Woodward WA and Sulman EP: Cancer stem cells: Markers or biomarkers? Cancer Metastasis Rev 27: 459-470, 2008.
28. Hay DC, Sutherland L, Clark J and Burdon T: Oct-4 knockdown induces similar patterns of endoderm and trophoblast differentiation markers in human and mouse embryonic stem cells. Stem Cells 22: 225-235, 2004.
29. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, et al: Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122: 947-956, 2005.
30. Wei H, Zhao MQ, Dong W, Yang Y and Li JS: Expression of c-kit protein and mutational status of the c-kit gene in osteosarcoma and their clinicopathological significance. J Int Med Res 36: 1008-1014, 2008.